Pirfenidone Is an Agonistic Ligand for PPARα and Improves NASH by Activation of SIRT1/LKB1/pAMPK

Nonalcoholic steatohepatitis (NASH) is recognized by hepatic lipid accumulation, inflammation, and fibrosis. No studies have evaluated the prolonged‐release pirfenidone (PR‐PFD) properties on NASH features. The aim of this study is to evaluate how PR‐PFD performs on metabolic functions, and provide...

Descripción completa

Detalles Bibliográficos
Autores principales: Sandoval‐Rodriguez, Ana, Monroy‐Ramirez, Hugo Christian, Meza‐Rios, Alejandra, Garcia‐Bañuelos, Jesus, Vera‐Cruz, Jose, Gutiérrez‐Cuevas, Jorge, Silva‐Gomez, Jorge, Staels, Bart, Dominguez‐Rosales, Jose, Galicia‐Moreno, Marina, Vazquez‐Del Mercado, Monica, Navarro‐Partida, Jose, Santos‐Garcia, Arturo, Armendariz‐Borunda, Juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049672/
https://www.ncbi.nlm.nih.gov/pubmed/32140659
http://dx.doi.org/10.1002/hep4.1474

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049672/
https://www.ncbi.nlm.nih.gov/pubmed/32140659
http://dx.doi.org/10.1002/hep4.1474

Ejemplares similares